Annovis Bio (NYSE: ANVS) closed an underwritten public offering raising approximately $10 million, plus a $1.5 million board investment, extending cash runway through Q2 2027 to fund a key 6‑month Phase 3 Alzheimer's symptomatic readout and an ensuing NDA submission.
The Phase 3 AD trial is ~75% enrolled; FDA agreed to integrate safety data from AD and PD trials into the AD NDA. An open‑label Parkinson's study is 28% enrolled and includes an AI digital biomarker device for real‑time monitoring.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
$10M gross proceeds closed from underwritten offering
Additional $1.5M investment from Board Chair Michael Hoffman
Cash runway extended to Q2 2027, covering 6‑month AD readout and NDA prep
Phase 3 AD trial ~75% enrolled, nearing full enrollment
FDA will integrate AD and PD safety data into the AD NDA
PD open‑label study 28% enrolled with AI digital biomarker
Negative
Public offering represents shareholder dilution risk
Cash runway only through Q2 2027, limited beyond NDA milestone
Phase 3 AD trial not yet fully enrolled (75% enrolled)
News Market Reaction – ANVS
-1.85%
3 alerts
-1.85%News Effect
-9.1%Trough Tracked
-$866KValuation Impact
$45.94MMarket Cap
0.9xRel. Volume
On the day this news was published, ANVS declined 1.85%, reflecting a mild negative market reaction.
Argus tracked a trough of -9.1% from its starting point during tracking.
Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
This price movement removed approximately $866K from the company's valuation, bringing the market cap to $45.94M at that time.
Gross proceedsapproximately $10 millionUnderwritten public offering closed April 10, 2026
Insider investment$1.5 millionInvestment from Board Chair Michael Hoffman
AD Phase 3 enrollment75% enrolledPivotal Alzheimer’s disease trial NCT06709014
PD OLE enrollment28% enrolledOpen-label extension Parkinson’s study NCT07284784
6-month readout timingQ1 2027Symptomatic data from Phase 3 AD trial
NDA runwaythrough Q2 2027Cash runway including offering and $1.5M insider investment
Disease-modifying assessment18-month assessmentPhase 3 AD trial long-term component
PD OLE duration36 monthsOpen-label extension treatment period
Market Reality Check
Price:$2.39Vol:Volume 6,639,077 is 7.75x...
high vol
$2.39Last Close
VolumeVolume 6,639,077 is 7.75x the 20-day average of 856,546, signaling unusually high trading interest around the offering close.high
TechnicalPrice at $1.62 is trading below the 200-day MA of $2.72 and well under the $5.50 52-week high.
Peers on Argus
ANVS fell 29.57% while key biotech peers like PSTV, RADX, and TPST showed gains,...
3 Up
ANVS fell 29.57% while key biotech peers like PSTV, RADX, and TPST showed gains, indicating the move was company-specific to this financing rather than sector-driven.
Fiscal 2025 results with progress in Phase 3 AD and PD programs.
Pattern Detected
Recent news has generally seen aligned price reactions, with positive R&D or IP updates lifting shares and the latest offering announcement triggering a sharp decline.
Recent Company History
Over the past month, Annovis reported fiscal 2025 results, advanced buntanetap into pivotal Phase 3 AD and PD studies, and highlighted strong IP, partnerships, and enrollment progress. News on Mar 16, Mar 19, Mar 31, and Apr 2 all saw positive price reactions. In contrast, the Apr 9 underwritten offering of $10 million in stock and warrants led to a -29.57% move, showing sensitivity to dilution despite previously constructive clinical and strategic updates.
Market Pulse Summary
This announcement closes a financing that, together with existing cash and a prior $1.5 million insi...
Analysis
This announcement closes a financing that, together with existing cash and a prior $1.5 million insider investment, extends Annovis’ runway through a planned 6‑month Phase 3 Alzheimer’s data readout in Q1 2027 and a subsequent NDA submission. The pivotal AD trial is 75% enrolled and the Parkinson’s open‑label extension is 28% enrolled, supported by an AI‑enabled digital biomarker platform. Key factors to watch include enrollment completion, safety integration across AD and PD, and timing and robustness of both the 6‑ and 18‑month efficacy analyses.
Key Terms
underwritten public offering, phase 3, new drug application (nda), open-label study, +4 more
8 terms
underwritten public offeringfinancial
"today announced the closing of an underwritten public offering raising approximately"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
phase 3medical
"a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
new drug application (nda)regulatory
"submission of a New Drug Application (NDA) for buntanetap to the U.S."
A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.
open-label studymedical
"and an ongoing open-label study in PD, Annovis is executing on all fronts."
An open-label study is a type of research where both the participants and the researchers know which treatment or intervention is being administered. This transparency can influence the results, making it important for investors to consider potential biases or limitations when evaluating the study’s findings. Understanding this helps assess the reliability of evidence supporting new products or therapies.
open-label extension (ole)medical
"In parallel, Annovis is conducting an open-label extension (OLE) study in PD patients"
An open-label extension (OLE) is a follow-up phase of a clinical trial where participants and researchers know the treatment being given, often after an initial blinded study. It allows for continued access to a promising therapy and provides additional safety and effectiveness data. For investors, it can signal ongoing interest in a treatment’s potential and help assess long-term benefits and risks.
biomarkermedical
"capture safety, efficacy, and biomarker data. The OLE study also incorporates"
A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.
ai-enabled digital biomarkertechnical
"incorporates an AI-enabled digital biomarker device, developed and provided by NeuroRPM,"
A ai-enabled digital biomarker is a health measurement derived from sensors or apps and interpreted by computer models to indicate a biological or behavioral state, such as heart rhythm, mobility, or sleep quality. For investors it matters because these measurable, software-driven signals can create new medical products, speed regulatory approval or reimbursement, and generate recurring data-driven revenue—think of it as a digital thermometer or fitness tracker that reliably translates raw signals into medically useful information.
u.s. food and drug administration (fda)regulatory
"NDA for buntanetap to the U.S. Food and Drug Administration (FDA)."
The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.
AI-generated analysis. Not financial advice.
Financing secures path to first NDA submission for buntanetap
6-Month symptomatic data readout anticipated Q1 2027
Alzheimer’s disease Phase 3 trial 75% enrolled
Parkinson's disease open-label study 28% enrolled
MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of an underwritten public offering raising approximately $10 million in gross proceeds. Combined with existing cash on hand as well as a recent $1.5 million investment from the Board of Directors Chair, Michael Hoffman, the financing extends Annovis' cash runway through Q2 2027, fully funding the Company's operations through a key symptomatic data readout of its Phase 3 AD trial and the anticipated submission of a New Drug Application (NDA) for buntanetap to the U.S. Food and Drug Administration (FDA).
“This financing is a decisive step forward for Annovis and for patients waiting for a novel Alzheimer’s treatment,” said Maria Maccecchini, Ph.D., President and CEO of Annovis. “We now have the resources to reach our first major regulatory milestone: the 6-month data readout from our Phase 3 AD trial and the NDA submission that follows. With enrollment nearing completion, NDA preparations launched, and an ongoing open-label study in PD, Annovis is executing on all fronts.”
Proceeds from this offering will primarily support the advancement of buntanetap through the pivotal Phase 3 AD trial (NCT06709014), which is approaching full enrollment with 75% of participants already enrolled. The trial is designed to provide two important milestones: a 6-month evaluation of symptomatic improvement and an 18-month assessment of potential disease modification, each followed by its own NDA submission. Preparations for the 6-month data readout and corresponding FDA filing are already underway.
Notably, the FDA has agreed to integrate safety data from both AD and PD populations from the Company’s completed and ongoing clinical trials in the NDA for AD, enabling regulatory efficiency that is expected to support a faster and more robust submission process.
In parallel, Annovis is conducting an open-label extension (OLE) study in PD patients (NCT07284784), which has enrolled 28% of participants since its inception in February 2026. The OLE study will test buntanetap for 36 months and capture safety, efficacy, and biomarker data. The OLE study also incorporates an AI-enabled digital biomarker device, developed and provided by NeuroRPM, that monitors symptom changes in real time, providing granular insight into buntanetap's therapeutic effects and further differentiating Annovis' clinical program.
About Annovis Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information: Annovis Bio Inc. 101 Lindenwood Drive Suite 225 Malvern, PA 19355 www.annovisbio.com
Investor Contact: Alexander Morin, Ph.D. Director, Strategic Communications Annovis Bio ir@annovisbio.com
FAQ
How much financing did Annovis (ANVS) raise on April 10, 2026 and who else invested?
Annovis raised approximately $10 million in an underwritten public offering and received a $1.5 million investment from the Board Chair. According to the company, combined funding extends operations through key Phase 3 milestones into Q2 2027.
What timeline does Annovis (ANVS) expect for the Phase 3 AD 6‑month data readout and NDA submission?
Annovis anticipates a 6‑month symptomatic data readout ahead of an NDA submission, with milestones targeted around Q1–Q2 2027. According to the company, NDA preparations are already underway to support that submission.
What is the enrollment status of Annovis' (ANVS) Phase 3 Alzheimer's trial and how material is it?
The Phase 3 AD trial is approximately 75% enrolled, nearing full enrollment. According to the company, this level of enrollment supports the planned 6‑month symptomatic and 18‑month disease‑modification assessments.
How will the FDA treat safety data for Annovis' (ANVS) AD NDA filing?
The FDA agreed to integrate safety data from both AD and PD populations into the AD NDA filing. According to the company, this regulatory approach is expected to improve efficiency and strengthen the submission package.
What is the status and purpose of Annovis' (ANVS) Parkinson's open‑label study?
The Parkinson's open‑label extension is 28% enrolled and will run up to 36 months to collect safety, efficacy, and biomarker data. According to the company, it also uses an AI digital biomarker device for real‑time symptom monitoring.
What does the April 2026 financing mean for ANVS shareholders’ near‑term outlook?
The financing funds operations through the next regulatory milestone but may dilute existing holders. According to the company, cash runway extends to Q2 2027 to cover the 6‑month readout and NDA preparations.
